EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Cyclosporin depresses pancreatic islet expression of antigens for islet cell autoantibodies in non obese diabetic mice



Cyclosporin depresses pancreatic islet expression of antigens for islet cell autoantibodies in non obese diabetic mice



Journal Of Autoimmunity. 9(1): 29-39



An unexpected observation led us to investigate whether a short course (7 days) of oral cyclosporin (CsA) at different doses (5, 10, 20 or 40 mg/kg/day) in nonobese diabetic (NOD) mice could modify the expression of islet antigens related to the autoimmune process. Analysis was performed on the last day of CsA administration, and then up to 60 days after CsA withdrawal. Antigen modulation was analysed by indirect immunofluorescence using islet-cell antibody (ICA)-positive human sera for ICA antigens, and by immunoperoxidase for glutamic acid decarboxylase 67Kd (GAD67). Concomitantly, beta-cell function was evaluated by in vivo glucose tolerance and insulin response from isolated islets. The severity of insulitis and histological damage to islets was quantified. We measured splenocyte and thymocyte subsets by cytofluorometry (CD4+ CD8-, CD4-CD8+, and double-positive thymocytes; Thy1-2+, CD3+, CD4+, and CD8+ spleen cells) and determined splenocyte mitogenesis in response to concanavalin A. Even when the lowest dose (5 mg/kg) was used, CsA concentrated in the islets. A graded reduction of ICA antigens was detected, showing no effect for 5 mg/kg/day but a significant dose-dependent reduction (P lt 0.01) with 10, 20 and 40mg/kg/day. GAD67 expression was also reduced P lt 0.03) in a CsA dose-dependent manner. On the other hand, only treatment with the highest CsA dose (40 mg/kg/day) induced glucose intolerance in vivo (P lt 0.02), decreased insulin sensitivity to glucose from isolated islets (P lt 0.03), reduced insulitis (P lt 0.03), and altered thymocyte and splenocyte phenotypes and mitogenesis (P lt 0.02). Moreover, the reversibility of the different effects was different: islet antigens were not completely recovered 2 months after CsA withdrawal, whereas other immunologic and metabolic effects obtained with the highest CsA dose were reversed within 15 days. Thus, a short course of low CsA doses in NOD mice produced a pancreatic concentration of the drug which reduced the expression of certain islet antigens for several weeks, whereas major effects on immunological parameters and islet insulin release occurred only with higher CsA doses and improved more rapidly.

(PDF emailed within 0-6 h: $19.90)

Accession: 008407820

Download citation: RISBibTeXText

PMID: 8845051

DOI: 10.1006/jaut.1996.0005



Related references

Pancreatic expression of antigens for islet cell antibodies in non-obese diabetic mice. Journal Of Autoimmunity. 8(4): 465-482, 1995

Non obese diabetic mice express high amounts of pancreatic glutamic acid decarboxylase and of antigens for islet cell antibodies. Diabetologia 36(SUPPL 1): A10, 1993

Effect of cyclosporin on insulitis and islet cell surface antibody in non obese diabetic mice. Diabetes Research & Clinical Practice (SUPPL 1): S299-S300, 1985

Evaluation of islet-specific autoantibodies in Japanese patients with insulin-dependent diabetes mellitus: a comparison between autoantibodies to glutamic acid decarboxylase, autoantibodies to 64 kDa islet cell protein and islet cell antibodies. Journal of Autoimmunity 7(6): 791-802, 1994

Longitudinal study of islet cell antibodies and insulin autoantibodies and development of diabetes in non-obese diabetic (NOD) mice. Clinical and Experimental Immunology 81(3): 400-405, 1990

Cytotoxic t lymphocytes recognizing islet cell antigens and mhc class i k d molecule in non obese diabetic mice. Diabetologia 32(7): 559A, 1989

Dendritic cell transfers protect non-obese diabetic mice from diabetes Dependence on islet antigen exposure and modification of cytokine profiles of islet infiltrating cells. Journal of Cellular Biochemistry Supplement 0(21A): 24, 1995

Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. International Immunology 6(12): 1927-1936, 1994

Pancreatic islet cell phenotype and endocrine function throughout diabetes development in non-obese diabetic mice. Autoimmunity 46(4): 259-268, 2013

Production of monoclonal antibodies to islet cell surface antigens using hybridization of spleen lymphocytes from non-obese diabetic mice. Diabetologia 26(5): 379-385, 1984

GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. Metabolism: Clinical and Experimental 62(1): 70-78, 2013

Effect of antiserum to monoclonal anti-islet cell surface antibody on pancreatic insulitis in non-obese diabetic mice. Diabetes Research and Clinical Practice 1(6): 315-321, 1985

The effect of pancreatic diabetogenic islet derived lymphocytes from non-obese mice on target cells expressing islet autoantigens. European Journal of Endocrinology 134(SUPPL 1): 19, 1996

Immunohistochemical identification of human pancreatic islet cell tumors using anti islet cell monoclonal autoantibodies. Cancer Immunology Immunotherapy 18(SUPPL): S39, 1984

Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction. Endocrinology 130(1): 37-42, 1992